Methicillin-resistant Staphylococcus aureus in German intensive care units during 2000-2003: Data from project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units)

Infection Control and Hospital Epidemiology

Volumn 27, Issue 2, 2006, Pages 146-154

  Meyer, Elisabeth ^a   Schwab, Frank ^b,c   Gastmeier, Petra ^d,e   Jonas, Daniel ^a   Rueden, Henning ^b,c,e   Daschner, Franz D ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e National Reference Centre for Surveillance of Nosocomial Infections   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GLYCOPEPTIDE; IMIPENEM; LINCOSAMINE DERIVATIVE; LINEZOLID; MACROLIDE; MEROPENEM; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; HOSPITAL LABORATORY; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; WILCOXON SIGNED RANKS TEST;

ANTI-INFECTIVE AGENTS; CROSS INFECTION; GERMANY; HUMANS; INTENSIVE CARE UNITS; METHICILLIN RESISTANCE; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33644904981     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/500619     Document Type: Article

References (29)

1. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003. Am J Infect Control 2003; 31:481-498.
2. Gastmeier P, Sohr D, Geffers C, Nassauer A, Dettenkofer M, Ruden H. Occurrence of methicillin-resistant Staphyhcoccus aureus infections in German intensive care units. Infection 2002; 30:198-202.
3. Herr CE, Heckrodt TH, Hofmann FA, Schnettler R, Eikmann TF. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 2003; 24:673-678.
4. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bonn, Germany: Antiinfectives Intellegence; 2003.
5. Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97:309-317.
6. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-252.
7. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in The Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004; 56:321-325.
8. Monnet DL, Frimodt-Moller N. Antimicrobial-drug use and methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2001; 7:161-163.
9. Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998; 19:552-559.
10. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9:1415-1422.
11. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215.
12. Gastmeier P, Geffers C, Sohr D, Dettenkofer M, Daschner F, Ruden H. Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). Am J Infect Control 2003; 31:316-321.
13. German Industrial Standard (DIN). Methods for the Determination of Susceptibility of Pathogens (Except Mycobacteria) to Antimicrobial Agents. Part 4. Evaluation Classes of the Minimum Inhibitory Concentration. Berlin: Beuth Verlag; 1998:1-11. DIN number 58940-4.
14. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA; 1999. NCCLS document M100-S9.
15. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive Care units (SARI). Infection 2003; 31:208-215.
16. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30:1089-1096.
17. Zuschneid I, Geffers C, Sohr D, Kohlhase C, Schumacher M, Gastmeier P, Ruden H. Accuracy of diagnosing nosocomial infections (NI) within the intensive care unit component of the German Surveillance System and correlations between findings and structural or process variables. In: Program and abstracts of the 13th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; April 2003; Arlington, VA. Abstract 18.
18. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20:31-36.
19. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003; 35: 843-850.
20. European Antimicrobial Resistance Surveillance System (EARSS). EARSS Annual Report 2002. Bilthoven, The Netherlands: National Institute of Public Health and the Environment; 2004.
21. Fridkin SK, Hill HA, Volkova NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US Hospitals. Emerg Infect Dis 2002; 8:697-701.
22. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002; 30:458-475.
23. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 2000; 44:1428-1437.
24. Westh H, Zinn CS, Rosdahl VT. An international multicenter study of antimicrobial consumption and resistance in Staphylococcus aureus isolates from 15 hospitals in 14 countries. Microb Drug Resist 2004; 10: 169-176.
25. Lopez-Lozano JM, Monnet DL, Yague A, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000; 14:21-31.
26. Monnet D, MacKenzie F, López-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10:1432-1441.
27. Monnet DL, Lopez-Lozano JM, Campillos P, Burgos A, Yague A, Gonzalo N. Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models. Clin Microbiol Infect 2001; 7(Suppl 5):29-36.
28. Talon D, Muller A, Thouverez M, Bertrand X. MRSA incidence as an indicator of infection control practices: do the results reflect the reality? J Hosp Infect 2004; 57:265-266.
29. Leegaard TM, Caugant DA, Froholm LO, Hoiby EA. Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect 2000; 6:290-293.